Eurofins Scientific SE (ERF)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 84.70 |
|---|---|
| 52-week range | 54.86 – 84.92 |
| Return, 1 month / 3 months | +11.2% / +28.1% |
| Return, 1 year / 3 years | +36.8% / +85.9% |
| Trend | Uptrend |
| RSI (14) | 75 |
| Volatility (1 year) | 27.5% |
| Worst drawdown (1 year) | -20.4% |
| Average daily value traded | 22.39M EUR |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eurofins Scientific is a laboratory testing company that provides analytical and bioanalytical services to clients in the food, pharmaceutical, environmental, agroscience and consumer products industries. Its laboratories test food and drink for safety and authenticity, support drug development and clinical trials, check water and soil quality, and verify the composition of consumer goods. The company is based in Luxembourg and serves customers around the world through a network of testing sites.
On this site Eurofins Scientific SE appears as a stock on the Euronext Paris (France), code ERF, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eurofins Scientific SE (ERF) trades on the Euronext Paris in France. It last closed at EUR 84.70 on 23 October 2026.
Its price-based Market X-Ray is 83 out of 100 (a strong price profile), ranking 15 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 36.8% and over the last three months it rose 28.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 95 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 25.0% | ||
| From 52-week high | 0.0% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 28.1% | ||
| 6-month return | 38.2% | ||
| 12-month return, skipping the last month | 23.0% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.4% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 22.39M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.2% |
|---|---|
| 1 month | +11.2% |
| 3 months | +28.1% |
| 6 months | +38.2% |
| 1 year | +36.8% |
| 3 years | +85.9% |
| 5 years | −12.2% |
Signals
| 50-day / 200-day average | 75.21 / 67.77 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.00 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Apr 2026 | EUR 0.7200 |
| 28 Apr 2025 | EUR 0.6000 |
| 3 Jul 2024 | EUR 0.5000 |
| 4 Jul 2023 | EUR 1.0000 |
| 5 Jul 2022 | EUR 1.0000 |
| 1 Jul 2021 | EUR 0.6800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.